Novartis first ventured into using electronic source (eSource) for the conduct of clinical trials in 2012 and has endeavored especially to promote more widespread adoption of eSource in order to improve trial operations and support better data integrity globally including Japan in collaboration with Clinical Ink (see appendix 2). We also continue to explore various technologies and adopt them into clinical trials for the conduction more efficiently and effectively.